Furthermore, using the TIDE website, it was determined that patients with downregulated expression levels of SOCS3 had a higher overall survival rate after ICB (PD-1 or PD-L1) treatment among kidney cancer, melanoma, and bladder cancer patients. This evidence concerns the gene CD274 and urinary bladder carcinoma.